Synthetic peptide-based DNA complexes for nonviral gene delivery

Smith, Louis C.; Duguid, J.G.; Wadhwa, Manpreet S.; Logan, Mark; Tung, Ching–Hsuan; Edwards, V.W.; Sparrow, James T.

doi:10.1016/s0169-409x(97)00111-7

Cited by 95 publications

(49 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26,46 To replace the adenovirus by less cytotoxic and less immunogenic agents, the effects of two small peptides were investi-gated: one binding integrins and the other with a SV40 large T antigen nuclear localization signal. These peptides did not permit the transfection of a 12 kb plasmid with PEI and DNA alone.…”

Section: Figure 4 Expression Of Adenoviral Proteins In Cells After Pementioning

confidence: 99%

Transfection of large plasmids in primary human myoblasts

et al. 2001

View full text Add to dashboard Cite

Section: Figure 4 Expression Of Adenoviral Proteins In Cells After Pementioning

confidence: 99%

Transfection of large plasmids in primary human myoblasts

et al. 2001

View full text Add to dashboard Cite

“…8a) and DNA-D2-JTS-1 (60-80 nm, Fig. 8b) complexes cannot substantially affect the delivery of the complexes into cells, as these dimensions fall within the range of average values favorable for the transport of these complexes into cells (100-200 nm) [14]. We believe that the more essential fact is that the triple DNA-D2-JTS-1 complex is to much extent unimodal (Fig.…”

Section: Analysis Of the Efficiency Of Transfection With Dna-d2-jts-1mentioning

confidence: 89%

Optimization of transfection properties of DNA-lysine dendrimer complexes

et al. 2005

Russ J Bioorg Chem

View full text Add to dashboard Cite

We studied the possibility of optimizing the DNA transfection properties of carriers based on lysine dendrimers of the third and the fifth generation, including those containing a chloroacetyl or a lipophilic palmitoyl moiety at C-end. The use of lysosome-destroying antibiotic chloroquine and an amphipathic polycationic nonadecapeptide JTS-1 was found to enhance the DNA transfecting properties of the lysine dendrimers. The triple complex including DNA, a lysine dendrimer of the third generation modified with lipophylic moieties of palmitic acid at its C-end, and JTS-1 was shown to be comparable in its transfecting activity to a complex containing Escort, a commercial cationic liposome carrier.

show abstract

“…90,91 A potential tumor-targeting peptide vector (cRGD-hK), which was intended to be systemically and repeatedly administered to patients with advanced solid tumors, was developed by Aoki et al 92 The peptide vector was composed of 36 amino-acid residues, CRGDCF(K[H-]KKK) 6 , incorporating a tumor-targeting RGD motif, a DNA-binding oligolysine and histidyl residues to facilitate the delivery into the cytosol (Figure 3c). In vitro (hepatoma and pancreatic cancer cells) transfection of the cRGD-hK/pDNA (luciferase expression plasmid) complexes was inhibited in the presence of either bafilomycin A1, which is an inhibitor of the vacuolar ATPase endosomal proton pump, or cycloRGDfV, which is an antagonist for integrin avb3.…”

Section: Rgd-functionalized Peptide-based Vectorsmentioning

confidence: 99%

A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy

et al. 2012

View full text Add to dashboard Cite

The development of effective treatments that enable many patients suffering from cancer to be successfully cured is highly demanded. Angiogenesis, which is a process for the formation of new capillary blood vessels, has a crucial role in solid tumor progression and the development of metastasis. Antiangiogenic therapy designed to prevent tumor angiogenesis, thereby arresting the growth or spread of tumors, has emerged as a non-invasive and safe option for cancer treatment. Due to the fact that integrin receptors are overexpressed on the surface of angiogenic endothelial cells, various strategies have been made to develop targeted delivery systems for cancer gene therapy utilizing integrin-targeting peptides with an exposed arginine-glycine-aspartate (RGD) sequence. The aim of this review is to summarize the progress and prospect of RGD-functionalized nonviral vectors toward targeted delivery of genetic materials in order to achieve an efficient therapeutic outcome for cancer gene therapy, including antiangiogenic therapy.

show abstract

Synthetic peptide-based DNA complexes for nonviral gene delivery

Cited by 95 publications

References 78 publications

Transfection of large plasmids in primary human myoblasts

Transfection of large plasmids in primary human myoblasts

Optimization of transfection properties of DNA-lysine dendrimer complexes

A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy

Contact Info

Product

Resources

About